COMP <GO>
PACS vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
PACS Group Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: PACS 4
— JNJ 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
LAST: $47.81 (-3.76%) • MKT CAP: $7.87B
roic
24.60%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PACS VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PACS | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 24.60% | 25.50% | -0.90 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.5x | 18.5x | -3.00 | PACS | /valuation <GO> |
| Free Cash Flow Yield | 2.11% | 2.97% | -0.86 | JNJ | /fcf-yield <GO> |
| Operating Margin | 5.90% | 34.70% | -28.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 3.60% | 28.50% | -24.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 29.40% | 6.00% | +23.40 | PACS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.24 | 5.59 | -3.35 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | PACS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.20% | -0.50 | PACS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.6 | 60.4 | -2.70 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.08 | -0.13 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.5x | 23.0x | +11.50 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.87B | $662.49B | -$654.63B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PACS REV | JNJ REV | PACS GROSS % | JNJ GROSS % | PACS FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.29B | $94.19B | 44.0% | 67.9% | $166.3M | $19.70B |
| FY 2024 | $4.09B | $88.82B | 44.0% | 69.1% | $183.4M | $19.84B |
| FY 2023 | $3.11B | $85.16B | 44.0% | 44.0% | -$76.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PACS // BETA 0.95
JNJ // BETA 1.08